Last updated: March 23, 2026
What is the drug represented by NDC 69315-0327?
NDC 69315-0327 corresponds to Remdesivir, marketed under the brand name Veklury. It is an antiviral medication approved for the treatment of COVID-19 in hospitalized patients, with emergency use authorizations in various countries.
Market Overview
Current Market Size
The global COVID-19 antiviral market, including remdesivir, reached an estimated value of USD 33 billion in 2022, with projected compound annual growth rate (CAGR) of 13% through 2027. Remdesivir constitutes approximately 20% of this market.
Key Players
- Gilead Sciences (manufacturer)
- Cipla (generic formulations)
- Dr. Reddy’s Laboratories
- Other regional generics producers
Distribution Channels
- Hospital procurement (largest segment)
- Specialty clinics
- Emergency use stockpiles
- International procurement via government contracts
Regulatory Status
- FDA: Approved for hospitalized COVID-19 patients
- EMA: Conditional approval
- WHO: Conditional recommendation for use in specific cases
Price Trajectory Analysis
Historical Pricing Trends
- 2020: Initial wholesale acquisition cost (WAC) in the US was approximately USD 2,340 per 100 mg vial ([2])
- 2021: Price increased to around USD 3,120 per 100 mg vial following demand surges and supply chain adjustments ([3])
- 2022-present: Industry reports suggest stabilization at USD 2,800–3,200 per vial in the US market
Market Dynamics Impacting Pricing
- Demand fluctuations: High during peaks of COVID-19 surges
- Generic competition: Entry of generics reduces prices; initial off-patent candidates projected by 2025
- Supply chain issues: Disruptions in raw material sourcing and manufacturing capacity influence pricing
- Regulatory changes: Repurposing approvals for other viral illnesses could expand indications, affecting demand
Price Projections (Next 3-5 Years)
| Year |
Estimated Wholesale Price per 100 mg Vial |
Key Drivers |
| 2023 |
USD 2,800 – 3,200 |
Market stabilization, increased generic entry, supply chain normalization |
| 2024 |
USD 2,400 – 2,800 |
Competition intensifies, demand stabilizes |
| 2025 |
USD 2,000 – 2,400 |
Significant generic penetration, manufacturing scale-up |
| 2026 |
USD 1,800 – 2,200 |
Broad generics adoption, pricing pressure |
| 2027 |
USD 1,600 – 2,000 |
Market saturation, cost-based pricing models |
Price Drivers
- Generic competition: Expected to drive prices down by 30–50% starting 2024
- Manufacturing costs: Estimated at USD 300–500 per vial, providing margin constraints
- Market demand: Will decline post-pandemic, but potential for other viral indications may sustain baseline demand
- Regulatory approvals: Additional indications could modify price points
Market Opportunities & Risks
Opportunities
- Expansion into treatments for other viral illnesses
- Use in outpatient settings if approved
- Supply to emerging markets through licensing
Risks
- Market oversupply resulting from aggressive generic entry
- Decreased demand once pandemic subsides
- Pricing pressures from health authorities and payers
Regulatory and Policy Influence
- Policy shifts around COVID-19 management could impact procurement volumes
- Price negotiation and reimbursement policies in major markets (US, EU, Asia) will affect net prices
- Nations like India and Brazil promote local production, lowering import reliance and prices
Key Takeaways
- The drug’s market remains sizeable but is shifting from pandemic-driven demand to a more stable, generic-driven environment.
- Prices are projected to fall sharply over the next five years, with a potential decline of up to 50% from current levels.
- Market saturation and increased manufacturing capacity will influence margins and access.
- Expansion into new indications could sustain demand but depends on clinical trial outcomes and regulatory approvals.
- Regulatory and policy environments increasingly pressure pricing, especially in value-based healthcare systems.
FAQs
What factors primarily influence remdesivir's price decline?
Increased generic competition, manufacturing scale-up, reduced demand post-pandemic, and regulatory price controls.
How does generic entry impact the market?
Generics reduce wholesale and retail prices by 30–50% and increase accessibility, shifting market share from Gilead to multiple regional producers.
Are there pipeline drugs likely to replace remdesivir?
Several antiviral agents are in development; however, none currently surpass remdesivir’s existing approvals for COVID-19. Pipeline drugs could influence future demand.
What regulatory moves could alter market projections?
Easing of approvals for additional indications, price negotiations by health authorities, or restrictive policies could modify demand and pricing.
How does regional variation affect pricing?
Prices are typically higher in developed countries (US, EU) due to pricing regulations, whereas emerging markets benefit from local manufacturing and lower prices.
References
- Gilead Sciences. (2022). Veklury (Remdesivir) product information. [Online]. Available at: https://www.gilead.com
- IQVIA. (2020). COVID-19 antiviral market report.
- Reuters. (2021). Remdesivir prices rise amid supply shortages.
